Occidental Take Lithium Leap With Berkshire Hathaway’s Subsidiary
Occidental Petroleum subsidiary TerraLithium partners with BHE Renewables to extract high-purity lithium from geothermal brine.
Stocks Dip Even With Traders Hopeful For September Rate Cut; Bonds Extend Rally, Oil Plummets: What’s Driving Markets Tuesday?
Growth concerns dragged stocks lower on Tuesday, with all major indices trading in the red as investors took a cautious tone on riskier assets.
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.
Snowflake & NVIDIA Team Up For AI Revolution: Details
Snowflake partners with NVIDIA to enable building customized AI apps on Snowflake's Cortex AI with NVIDIA AI Enterprise software and NeMo Retriever microservices.
Apple GPT, AI-Siri, VisionPro’s Global Rollout: What To Expect At WWDC 2024
Apple to unveil advancements at WWDC 2024 with focus on AI integration across ecosystem. New features include audio summarization and photo editing. Apple GPT to compete with Chat GPT-4 and Gemini. Vision Pro headset to have international rollout.
Trip.Com Stock Is Trading Lower Tuesday: What’s Going On?
Trip.com Group Limited (NASDAQ: TCOM) to offer $1.3 billion in convertible senior notes to repay debt and expand operations, while repurchasing shares.
Rio Tinto Invests $143M in Low-Emission Steel Research And Development
Rio Tinto invests $143 million in low-emission steelmaking research and development facility in Western Australia, targeting a 95% reduction in CO2 emissions.
Gear Shift In Japan: Toyota & Other Auto Giants Reportedly Under Inspection Over Certification Scandal
Japan's transport ministry inspected Toyota Motor Corporation's headquarters and found irregularities, leading to broader repercussions in the industry.
GSK’s Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or refractory multiple myeloma compared to bortezomib with PomDex.
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with potential milestones and royalties up to $577 million.